Skip to main content
Indivior PLC logo

Indivior PLC — Investor Relations & Filings

Ticker · INDV ISIN · GB00BN4HT335 LEI · 213800V3NCQTY7IED471 IL Manufacturing
Open in API
Filings indexed 1,983 across all filing types
Latest filing 2024-07-26 Director's Dealing
Country GB United Kingdom
Listing IL INDV

About Indivior PLC

https://www.indivior.com/en

Indivior PLC is a global pharmaceutical company that develops, manufactures, and sells medicines to treat substance use disorders (SUD) and serious mental illnesses. The company's primary focus is on pioneering treatments for opioid use disorder (OUD), with a portfolio centered on buprenorphine-based prescription pharmaceuticals. Through its research and development efforts, Indivior aims to address the complex challenges of addiction and behavioral health by providing innovative, life-transforming therapies for patients worldwide.

Recent filings

Filing Released Lang Actions
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is explicitly labeled with an 'RNS Number' and states, 'This information is provided by RNS, the news service of the London Stock Exchange.' The content details a 'NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES ('PDMR')' involving a Non-Executive Director purchasing company shares. This type of insider transaction disclosure is a specific regulatory filing. While it relates to director dealings (DIRS), the format and source (RNS) strongly suggest it is being disseminated as a general regulatory announcement. Since 'Director's Dealing' (DIRS) is a specific category for this content, it is the most appropriate classification over the general 'Regulatory Filings' (RNS) fallback, even though RNS is the distribution channel.
2024-07-26 English
SHARE REPURCHASE PROGRAM
Regulatory Filings
2024-07-25 English
6-K
Regulatory Filings
2024-07-25 English
Share Repurchase Program
Transaction in Own Shares Classification · 100% confidence The document is an official announcement released via RNS (RNS Number : 7423X) on July 25, 2024. The primary subject is the announcement of a new $100 Million Share Repurchase Program and the acceleration of the current one. A share repurchase program is a transaction where a company buys back its own shares, which directly corresponds to the definition of 'Transaction in Own Shares' (Code: POS). Although it involves capital management, the specific action described is the repurchase itself, not a general financing update (CAP) or a broad capital change (SHA). Since this is a specific announcement of a transaction in own shares, POS is the most accurate classification.
2024-07-25 English
Half-year Report
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the second quarter and first half of 2024 (H1/Q2 2024). It contains detailed financial statements, including net revenue, operating profit/loss, net income, EPS, and cash flow data, as well as management's analysis of business performance, product highlights, and updated FY 2024 guidance. It is not a mere announcement or certification, but a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q2 2024
2024-07-25 English
TRANSACTION IN OWN SHARES
Regulatory Filings
2024-07-23 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.